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Abstract
Background: Nontypeable Haemophilus influenzae (NTHi) is a gram-negative bacterium that
causes otitis media in children as well as other infections of the upper and lower respiratory tract
in children and adults. We are employing genetic strategies to identify and characterize virulence
determinants in NTHi. NTHi is naturally competent for transformation and thus construction of
most mutants by common methodologies is relatively straightforward. However, new
methodology was required in order to construct unmarked non-polar mutations in poorly
expressed genes whose products are required for transformation. We have adapted the lambda
red/FLP-recombinase-mediated strategy used in E. coli for use in NTHi.
Results: A cassette containing a spectinomycin resistance gene and an rpsL gene flanked by FRT
sites was constructed. A PCR amplicon containing 50 base pairs of DNA homologous to the 5' and
3' ends of the gene to be disrupted and the cassette was generated, then recombineered into the
target NTHi gene, cloned on a plasmid, using the lambda recombination proteins expressed in E.
coli DY380. Thus, the gene of interest was replaced by the cassette. The construct was then
transformed into a streptomycin resistant NTHi strain and mutants were selected on
spectinomycin-containing growth media. A plasmid derived from pLS88 with a temperature
sensitive replicon expressing the FLP recombinase gene under the control of the tet operator/
repressor was constructed. This plasmid was electroporated into the NTHi mutant at the
permissive temperature and FLP expression was induced using anhydrotetracycline. The
recombinase recognizes the FRT sites and eliminates the antibiotic cassette by site-specific
recombination, creating the unmarked non-polar mutation. The plasmid is cured by growth of cells
at the restrictive temperature.
Conclusion: The products of the genes in the NTHi pilABCD operon are required for type IV pilus
biogenesis and have a role in transformation. We demonstrated the utility of our methodology by
the construction of a non-polar pilA mutation in NTHi strain 2019 and complementation of the
mutation with a plasmid containing the pilA gene. Utilization of this approach allowed us to readily
generate unmarked non-polar mutations in NTHi genes.
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Nontypeable Haemophilus influenzae (NTHi) is a gram-
negative bacterium, which is a major cause of otitis media
[1,2]. The organism also causes pneumonia and other res-
piratory tract diseases in humans [1,2]. Type IV pili (Tfp)
mediate adherence, twitching motility, and play a role in
transformation (reviewed by Craig et al [3]). We previ-
ously demonstrated that NTHi produce Tfp under defined
environmental conditions. These Tfp are responsible for
twitching motility, Tfp-mediated adherence and contrib-
ute to biofilm development [4-6]. The products of the pil-
ABCD gene cluster play a role in Tfp biogenesis [4,7,8].
The pilA gene is predicted to encode the major pilin subu-
nit. The PilB protein is homologous to hexameric secre-
tion ATPases and the PilC protein has homology to inner
membrane proteins required for Tfp pilus assembly in
other organisms. PilD is predicted to be the prepilin pepti-
dase. These genes are in an operon, which necessitates the
construction of non-polar mutants in order to carefully
define the role of each gene product.
In NTHi, non-polar mutants have been constructed using
the non-polar kanamycin resistance cassette designed by
Menard et al [9], see for example Mason et al [10]. This
kanamycin resistance gene is promoter-less; thus, tran-
scription is driven from the promoter of the operon. The
level of transcription must therefore be at a level sufficient
to confer a kanamycin-resistant phenotype to the mutant
under normal growth conditions. Alternatively, a non-
polar mutant can be constructed in two steps. First, a
mutant is constructed using standard methodologies [11]
in which a gene has been interrupted with a cassette con-
taining both a selectable and counter-selectable marker.
Then, DNA containing an in-frame deletion of the gene of
interest together with flanking chromosomal DNA 5' and
3' of the deleted gene is transformed into the mutant.
Mutants containing the in-frame deletion are isolated by
selection against the counter-selectable marker. Neither of
these methodologies is suitable for use with genes whose
products are required for transformation since the genes
are poorly expressed under normal growth conditions and
mutants deficient in the expression of these genes cannot
be transformed. We thus adapted the methodologies
employed by Wanner and coworkers [12,13] to construct
non-polar mutations in NTHi.
Results and discussion
Construction of a non-polar mutant in the NTHi pilA gene
Mutations have been engineered into the E. coli chromo-
some using the lambda phage recombinase to catalyze the
site-specific insertion of a PCR amplicon containing 50 bp
homology arms and a cassette flanked by FRT (FLP recom-
binase target) sites, replacing the gene of interest [12,13].
Given the restriction barriers present in NTHi strains, it
was necessary to perform the insertional inactivation of
the NTHi genes of interest by cloning the gene together
with flanking sequences onto a plasmid, then insertion-
ally inactivating the gene in E. coli before moving the
mutation into NTHi using the natural transformation sys-
tem [11]. E. coli strain DY380 has previously been used for
engineering plasmids using the products of the phage
lambda recombinase genes [14]. This strain is lysogenized
with a defective lambda phage that expresses the recombi-
nase genes under the control of the temperature sensitive
λcI857 repressor and thus is a suitable host for recom-
bineering [15]. In order to construct a pilA mutation in
NTHi, the pil gene cluster was first amplified from NTHi
strain 2019, then cloned into pGEM-T Easy and trans-
formed into E. coli strain DY380 to form strain
DY380(pRSM2855).
The plasmid pKD13 contains the kanamycin resistance
gene from Tn5 flanked by FRT sites recognized by the FLP
recombinase [13]. We modified pKD13 so that it con-
tained a spectinomycin resistance gene; in NTHi, spectin-
omycin provides a strong selectable marker with little
background. The normal allele of an rpsL gene from Neis-
seria gonorrhoeae (designated rpsLNg) was also added to the
construct to provide a counter selectable marker [16]. This
plasmid was designated pRSM2832. Employing
pRSM2832 as a template, a PCR amplicon was generated
using the strategy of Baba et al [12]. The 5' primer was
designed to include 50 nt 5' to and including the ATG start
codon of the pilA gene. The 3' primer was designed to con-
tain the complement of the last 21 nt including the stop
codon of the pilA gene. Both primers contained regions
homologous to the cassette containing the spectinomycin
resistance gene and the rpsLNg gene (Figure 1). The ampli-
con (Figure 2A) was electroporated into E. coli strain
DY380(pRSM2855) after heat shock and spectinomycin-
resistant clones were isolated. A plasmid containing the
anticipated insertion/deletion mutation in the pilA gene
was saved as pRSM2857 (Figure 2C).
NTHi strain 2019 is a well-characterized isolate from a
patient with chronic bronchitis [17-19]. The pRSM2857
insert was separated from the plasmid backbone by diges-
tion with NcoI and NsiI, then transformed into a strepto-
mycin-resistant derivative of NTHi strain 2019,
designated NTHi strain 2019 rpsL, using the MIV method-
ology [11]. A strain containing the anticipated insertion/
deletion mutation in the pilA gene was saved as NTHi
strain 2019 rpsLΔpilA::spec-rpsLNg. The next step in the
construction was the removal of the cassette, which is
flanked by FRT sites, by expression of the FLP recombi-
nase.
We constructed a temperature sensitive derivative of
pLS88, a plasmid that replicates in NTHi and cloned the
FLP recombinase gene into this construct under control ofPage 2 of 9
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nated pRSM2947, was electroporated into NTHi strain
2019 rpsLΔpilA::spec-rpsLNg and kanamycin resistant
clones were isolated. One clone was saved as NTHi strain
2019 rpsLΔpilA::spec-rpsLNg (pRSM2947). Expression of
the FLP recombinase was induced in this strain, then
clones were isolated at 37°C on streptomycin-containing
medium. One streptomycin-resistant clone was saved as
NTHi strain 2019 rpsLΔpilA for further characterization.
The pil region in the mutant is represented in Figure 2D.
The NTHi strain 2019 rpsLΔpilA mutant was not 
transformable; the phenotype was complemented by the 
pilA gene
The product of the genes in the pil gene cluster is required
for transformation using the MIV methodology [4]. Trans-
formability of the ΔpilA mutant was tested using a modi-
fication of the MIV methodology [4]. In order to generate
a DNA substrate for transformation, we cloned, then
insertionally inactivated, the H. influenzae strain Rd cya
gene with a non-polar kanamycin cassette to form
pRSM2948 (data not shown). Plasmids were digested
with NotI. The linear DNA fragment containing the inter-
rupted cya gene was transformed into the NTHi strain
2019 rpsLΔpilA and strain 2019 rpsL using the modified
MIV methodology. Transformants were selected on choc-
olate agar containing kanamycin. Transformation effi-
ciency (number of transformants/μg of DNA) is shown in
Table 1. Approximately 5 × 105 transformants/μg of DNA
was obtained with strain 2019 rpsL, while transformants
were not detected with the mutant under these condi-
tions. We cloned the pilA gene into a shuttle vector form-
ing pRSM2848 and electroporated the construct into
NTHi strain 2019 rpsLΔpilA. We then tested the transform-
ability of the complemented strain using the interrupted
cya gene as described above. Approximately 1.5 × 105
transformants/μg of DNA was obtained with the comple-
mented strain (Table 1).
Although the putative functions of the pilB, pilC and pilD
genes make it likely that the products of these genes are
required for transformation, we demonstrated that a polar
mutation in the pilA gene could not be complemented
with plasmid pRSM2848, the plasmid expressing the pilA
gene. A polar pilA mutant, designated 2019 pilA::ΩKm2,
was constructed by insertion of the ΩKm2 cassette into
the pilA gene as described [4]. As anticipated, this mutant
is not transformable and the mutation could not be com-
plemented with the cloned pilA gene (Table 1).
Conclusion
We have developed a new methodology for the construc-
tion of mutants in NTHi. This methodology was devel-
oped to overcome technical issues related to the
construction of non-polar mutants in poorly expressed
genes whose products are required for transformation.
However, the method is straightforward and robust. We
have successfully constructed over 20 mutants using this
method and now construct all H. influenzae mutants in
our laboratory using this method. The methodology
should also be applicable to other naturally transformable
members of the Pasteurellaceae family that support the
replication of pLS88 derivatives.
Methods
Bacterial strains, plasmids and growth conditions
NTHi strain 2019 is a well characterized strain from a
patient with chronic bronchitis [17-19]. NTHi strain 2019
rpsL was constructed by Apicella and coworkers. This
strain contains a mutation resulting in a K43R modifica-
tion in RpsL; the strain is resistant to 1 mg of streptomy-
cin/ml. Both strains were kindly provided by Dr. Michael
Apicella. NTHi strains were grown on chocolate agar or in
Brain Heart Infusion broth supplemented with 2 μg of
NAD/ml and 2 μg of heme/ml (sBHI). Growth media
were supplemented with spectinomycin, kanamycin,
chloramphenicol or streptomycin at 200 μg/ml, 20 μg/ml,
1 μg/ml or 1 mg/ml, respectively, when appropriate. E. coli
Generation of a PCR amplicon for insertion/deletion muta-genesis of the pilA geneFigure 1
Generation of a PCR amplicon for insertion/deletion 
mutagenesis of the pilA gene. In Panel A, the pilA gene 
from NTHi strain 2019 is shown. Homology arm 1 (H1) con-
tains 50 base pairs of DNA 5' to and including the ATG start 
codon of pilA. Homology arm 2 (H2) contains the comple-
ment of the last 21 base pairs of the pilA gene and 29 base 
pairs immediately downstream of the pilA gene. In Panel B, 
the template region of pRSM2832 is shown. Primer H1P1 
contains the sequence from H1 and 20 base pairs of DNA 
homologous to the 5' end of the cassette (P1). Primer H2P2 
contains the sequence from H2 and 20 base pairs of DNA 
homologous to the 3' end of the cassette. PCR amplification 
of pRSM2832 with primers H1P1 and H2P2 (primers 5 and 6) 
yielded the product shown in Panel C.
ATG
pilA
H2
H1
FRT
FRTrpsL spectinomycinH1
H2
P1
P2FRT
FRTrpsL spectinomycinH1
A
B
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were supplemented with spectinomycin, kanamycin,
chloramphenicol or ampicillin at 50 μg/ml, 20 μg/ml, 30
μg/ml or 50 ug/ml, respectively, when appropriate. Strain
DY380 was grown at 32°C. A complete list of strains and
plasmids used in this study is provided [see Additional file
1].
Construction of a template plasmid containing a cassette 
with a spectinomycin resistance gene and an rpsL gene 
flanked by FRT sites
The plasmid pKD13 has been used as a template plasmid
for the construction of a complete set of E. coli strains with
mutations in each non-essential gene [12]. We modified
this vector by replacing the kanamycin resistance gene
with a spectinomycin resistance gene and the rpsLNg gene.
The plasmid pSpecR [20] was digested with EcoRV and the
EcoRV fragment containing the spectinomycin resistance
gene was cloned into the EcoRV site of pWSK30 [21]. A
plasmid with the correct restriction map was saved as
pRSM2790. The counter selectable marker, rpsLNg, was
amplified by PCR using genomic DNA purified from N.
gonorrhoeae strain FA1090 and primers 1 and 2 containing
BamHI and NotI sites at the 5' end, respectively (Table 2).
The amplicon was digested with NotI and BamHI, then
cloned into the plasmid pRSM2790 that had been
digested with these enzymes. A plasmid with the correct
insert was identified and saved as pRSM2830. The kan-
amycin cassette from pKD13 was eliminated by PCR
amplification of a portion of pKD13 using primers 3 and
4 which face outward from inside the FRT sites. The spec-
tinomycin resistance gene-rpsLNg cassette was isolated
from the pRSM2830 by digestion with SacI and XhoI and
cloned into the pKD13-derived PCR product. Clones were
selected on LB-agar containing spectinomycin. The plas-
mid from a spectinomycin-resistant clone was character-
ized by restriction digestion and sequencing, then saved as
pRSM2832.
Construction of a non-polar pilA mutantFigure 2
Construction of a non-polar pilA mutant. The PCR amplicon from Figure 1 is shown in Panel A. The cloned pilABCD 
region of pRSM2855 is shown in Panel B. The amplicon was electroporated into E. coli DY380(pRSM2855) and the lambda 
recombinase genes were induced by temperature shock. Spectinomycin-resistant clones were selected. The insert region of 
plasmid pRSM2857 is shown in Panel C. Plasmid pRSM2857 was linearized and transformed into NTHi strain 2019 rpsL; spec-
tinomycin-resistant clones were isolated. NTHi strain 2019 rpsLΔpilA::spec-rpsLNg was saved, then transformed with pRSM2947 
at the permissive temperature; kanamycin resistant clones were isolated. Expression of the FLP recombinase resulted in the 
loss of the spectinomycin resistance gene-rpsLNg cassette; growth at 37°C resulted in the loss of the plasmid. The pil region of 
NTHi strain 2019 rpsLΔpilA is depicted in Panel D.
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Since lambda recombinase requires less than 50 bp of
homology for efficient recombination, PCR primers of
approximately 70 nt in length were designed using the
strategy of Baba et al [12]. The 5' PCR primer (primer 5)
had a 50 nt homology arm (H1) including the sequence
upstream of pilA as well as the pilA start codon and the 20
nt sequence 5'-ATTCCGGGGATCCGTCGACC-3' (P1)
which is complementary to sequence 5' of the spectino-
mycin resistance gene-rpsL cassette (Figure 1). The 3'
primer (primer 6) contained the complement of the last
21 nt of the pilA gene including the termination codon
and 29 nt downstream (H2) as well as the 20 nt sequence
5'-TGTAGGCTGGAGCTGCTTCG-3' (P2) which is com-
plementary to sequence 3' of the spectinomycin resistance
gene-rpsLNg cassette. A PCR amplicon was generated using
these primers together with pRSM2832 as the template.
Amplification was performed in a 50 μl reaction contain-
ing 1 U Phusion High Fidelity DNA Polymerase (New
England Biolabs), 25 ng pRSM2832 DNA, 0.4 μM of each
primer, and 200 μM dNTPs under the following condi-
tions: 98°C for 30 seconds, 30 cycles of 98°C for 10 sec-
onds, 51°C for 20 seconds, 72°C for 3 minutes, and a
final extension of 72°C for 10 minutes. The amplicon
thus contains the spectinomycin resistance gene-rpsL cas-
sette flanked by the homology arms H1 and H2.
Construction of a pilA mutant in NTHi strain 2019 rpsL 
containing the spectinomycin resistance gene-rpsLNg 
cassette
The pilABCD gene cluster of NTHi strain 2019 as well as
227 bp 5' of the pilA gene was amplified by PCR from
genomic DNA purified from NTHi strain 2019 using
primers 7 and 8 and cloned into pGEM-T Easy (Promega)
(Figure 2B). The nucleotide sequence of the NTHi strain
2019 pilABCD gene cluster is 94% identical to the gene
cluster in strain 86-028NP (Genbank Accession #
CP000057). Plasmid DNA was purified, verified by
restriction digestion, and sequenced. A clone with the cor-
rect sequence was identified and saved as pRSM2855.
Plasmid pRSM2855 was transformed into the E. coli strain
DY380 at 32°C and clones were selected on LB agar con-
taining ampicillin. Strain DY380 contains a defective
lambda prophage with a temperature sensitive repressor
Map of plasmid pRSM2947Figure 3
Map of plasmid pRSM2947. The plasmid contains: the FLP 
recombinase gene under the control of the tet regulatory 
system; a temperature sensitive replicon suitable for use in 
NTHi; a ColE1 origin that is functional in E. coli and a kan-
amycin resistance marker.
5       5   9   1    b   p   
p       F    L      P   
pRSM2947
Table 1: Transformation of strain 2019 derivatives
Number of transformants/μg of DNA
Strains
2019 rpsL 2019 rpsLΔpilA 2019 rpsLΔpilA (pRSM2848)
Experiment #1 5.4 × 105 ND 1.3 × 105
Experiment #2 4.8 × 105 ND 1.7 × 105
Strains
2019 2019 pilA::ΩKm2 2019 pilA::ΩKm2 (pRSM2848)
Experiment #3 3.9 × 103 ND ND
Experiment #4 5.6 × 103 ND ND
ND is not detected.Page 5 of 9
(page number not for citation purposes)
BMC Molecular Biology 2008, 9:101 http://www.biomedcentral.com/1471-2199/9/101[14]. In this strain, the lambda recombinase genes are
actively transcribed after temperature shock at 42°C.
To construct a plasmid containing a marked deletion of
the pilA gene, 200 ng of PCR product containing the spec-
tinomycin resistance gene-rpsLNg cassette was electropo-
rated into E. coli DY380(pRSM2855) that had been heat
shocked at 42°C for 15 minutes prior to preparation of
electrocompetent cells as described by Lee et al [14].
Clones were then selected at 32°C on LB agar containing
spectinomycin. A plasmid containing a deletion of the
pilA gene with an insertion of the cassette was identified
and saved as pRSM2857 (Figure 2C).
Plasmid pRSM2857 was digested with NcoI and NsiI to
release the insert from the pGEM-T Easy vector backbone,
then transformed into NTHi strain 2019 rpsL using the
MIV methodology [11]. Clones were selected on choco-
late agar supplemented with spectinomycin. Putative
mutants were screened for streptomycin sensitivity on
chocolate agar containing streptomycin. The genotype of
presumptive mutants was further characterized by PCR
Table 2: Oligonucleotide primers
Primer Sequence
primer 1 GCGGATCCCCGACTGATTGTGAGGGATGTCGG
primer 2 GCGCGGCCGCCCGACTGATTGTGAGGGATGTCGG
primer 3 GCGAGCTCGCATCGCCTTCTATCGCCTTCTTG
primer 4 GCCTCGAGCAGCCCTTGCGCCCTGAGTG
primer 5 CTTTTCACAATGTTGTCGCTAACAAAGGCTTAATAAAAGGAAAATGAATGATTCCGGGGATCCGTCGACC
primer 6 ACGCTGAGTATGAAGTAAAGCATAGCTCGTCATTTTGTGACACTTCTGCATGTAGGCTGGAGCTGCTTCG
primer 7 GCGCGTCGACAACCAATAAGGAAATA
primer 8 CGAGGCAATGGATCAACAGAAG
primer 9 GGGCGTTTATCGAAGTGAGG
primer 10 TCAACCCCTAGCCAAAGAC
primer 11 CGCGGATCCTGCCGCCTGTTTTTCCTGCTCATT
primer 12 CTGTTATCCTTAAATCTCGCTTATTAGGTGTGCTTGTATTTCTTGGG
primer 13 CCCAAGAAATACAAGCACACCTAATAAGCGAGATTTAAGGATAACAG
primer 14 CGCGGATCCGCGGCCGCGTGACACGACGATGCTAAA
primer 15 ATATAATGCGGCCGCTACGGTTATCCACAGAATCA
primer 16 ATATAATGCGGCCGCCTCACTGATTAAGCATTGG
primer 17 CGCGGATCCCGATGGGTGGTTAACTCGAC
primer 18 CGCGGATCCACAGGACGGGTG
primer 19 GCACGCGTTCGTCAAATATTACGGATATTAA
primer 20 GCACGCGTTCATTGTGTGACACTTCCG
Restriction endonuclease cleavage sites are shown in bold.Page 6 of 9
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10, followed by sequencing.
Construction of the FLP Recombinase containing plasmid, 
pRSM2947
Deletion of the cassette to generate the non-polar muta-
tion in NTHi strain 2019 rpsL requires the activity of the
FLP recombinase. We constructed a temperature sensitive
plasmid containing the FLP recombinase gene under the
control of the tet promoter/repressor system. Briggs and
Tatum previously reported the construction of a plasmid
with a temperature sensitive replicon suitable for use in
members of the Pasteurellaceae family [22]. This plasmid
has the same replicon as the plasmid pLS88 [23]. A point
mutation of G to A at base 2196 of pLS88 was introduced
into a fragment of pLS88 containing the replicon and kan-
amycin resistance gene using overlap PCR. Briefly, ampli-
cons 1 and 2 corresponding to NT 1715 to 2220 and 2174
to 4093 of pLS88 were generated with primers 11 and 12
or primers 13 and 14, respectively, using pLS88 DNA as
template. Amplicon 3 was generated with primers 11 and
14, which both contain BamHI sites, using amplicons 1
and 2 as template. The amplicon was digested with
BamHI, and self-ligated. The ligation mixture was trans-
formed into H. influenzae strain Rd by electroporation.
Plasmid-containing strains were selected by growth at
32°C on chocolate agar containing kanamycin. Strains
containing the correct plasmid were identified by screen-
ing for growth at 32°C, but absence of growth at 37°C on
chocolate agar containing kanamycin. A temperature sen-
sitive plasmid was saved as pRSM2865. This intermediate
plasmid is 2.3 Kb in size and contains unique NotI and
BamHI sites. The presence of the mutation in pRSM2865
was confirmed by DNA sequencing. Although pLS88 is
stably maintained in E. coli, pRSM2865 could not be
maintained in E. coli, even when grown at 32°C. Thus, for
convenience, a fragment of pUC19 containing the ColE1
replicon was amplified with primers 15 and 16; both
primers contain a NotI site. The resulting amplicon was
digested with Not I, then cloned into NotI-digested
pRSM2865. After transformation into E. coli strain DH5α,
a plasmid with the correct restriction map was saved as
pRSM2866. Using pFT-A [24] as template and primers 17
and 18, which contain BamHI sites, an amplicon was gen-
erated which contained the FLP recombinase gene under
control of the tet promoter/repressor system flanked by
BamHI sites. The amplicon was digested with BamHI and
the product ligated to BamHI-digested pRSM2866. The
ligation mixture was transformed into DH5α and clones
selected on LB agar containing kanamycin. A plasmid
with the correct restriction map was identified and saved
as pRSM2947 (Figure 3).
Construction of pilA mutants in NTHi strain 2019 
background
In order to construct an in-frame, non-polar deletion of
the cloned pilA gene in NTHi strain 2019 rpsL, plasmid
pRSM2947 was transformed by electroporation into
NTHi strain 2019 rpsLΔpilA::spec-rpsLNg and transform-
ants were selected at 32°C on chocolate agar containing
kanamycin. Clones were grown at 32°C in sBHI broth
supplemented with kanamycin until a final absorbance
(600 nm) of 0.30 was reached. The FLP recombinase was
then induced with 200 ng of anhydrotetracycline/ml for 2
hours, shaking (180 rpm) at 32°C. Unmarked mutants
were then selected by growth at 37°C on chocolate agar
supplemented with streptomycin. Mutants were then
screened for loss of both spectinomycin and kanamycin
resistance genes and the genotype was verified by PCR and
sequencing (Figure 2D). Although convenient, the strep-
tomycin counterselection is not necessary. After induction
of the FLP recombinase using our methodology, the cas-
sette is resolved in approximately 2% of the clones; thus,
it is possible to identify mutants by screening. A detailed
protocol for mutant construction in NTHi strains is pro-
vided [see Additional file 2].
A polar mutation in the pilA gene of strain 2019 was con-
structed as described [4]. The mutant is designated 2019
pilA::ΩKm2.
Complementation of the pilA mutation in NTHi strains 
2019 rpsLΔpilA and 2019 pilA::ΩKm2
The plasmid pPIL1 containing the NTHi pilABCD gene
cluster [4] was PCR amplified with primers 19 and 20,
which face outward from the 3' end of pilA and the 3'end
of pilD. The primers both contain MluI sites on their 5'
ends. The amplicon was digested with MluI, self-ligated,
and transformed into H. influenzae strain Rd. The resulting
plasmid contained the pSPEC1 backbone, the pilA gene,
and a small ORF containing the 5' portion of the pilB gene
cloned in-frame with the 3' end of the pilD gene. A clone
with the correct restriction map was sequenced, then
saved as pRSM2848. The plasmid pRSM2848 was then
transformed into NTHi strains 2019 rpsLΔpilA and 2019
pilA::ΩKm2.
Cloning and insertional inactivation of the cya gene
We cloned and insertionally inactivated the cya gene. This
interrupted gene was used to test the strains for their abil-
ity to be transformed. The cya gene from H. influenzae
strain Rd and approximately 1 Kb of flanking DNA 5' and
3' to the gene were amplified and cloned into pGEM-T
Easy essentially as described for construction of
pRSM2855. A clone with the correct restriction map was
saved as pRSM2921. The non-polar kanamycin cassette
[9] was cloned into KpnI- and BamHI-digested
pRSM2921 as a KpnI to BamHI fragment. After ligationPage 7 of 9
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ally inactivated cya gene was identified and saved as
pRSM2948. The cloned cya gene was also insertionally
inactivated by cloning a BamHI fragment containing the
chloramphenicol cassette from pUCΔEcat into BglII-
digested pRSM2921. As plasmid containing the insertion-
ally inactivated cya gene was saved as pRSM3004.
Determination of transformation efficiency
Transformation efficiency was determined in strains 2019
rpsL, 2019 rpsLΔpilA and 2019 rpsLΔpilA(pRSM2848).
DNA from NotI-digested pRSM2948 was incubated with
cells treated to induce competence using the modified
MIV methodology; transformants were identified on
chocolate agar plates containing kanamycin. Similarly,
transformation efficiency was determined in strains 2019
pilA::ΩKm2 and 2019 pilA::ΩKm2(pRSM2848) using lin-
earized pRSM3004 as above, except that transformants
were selected on chloamphenicol-containing medium.
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